Lemaitre Vascular (LMAT) Common Equity (2010 - 2026)

Lemaitre Vascular (LMAT) has reported Common Equity for 17 consecutive years, with $420.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Common Equity rose 15.9% year-over-year to $420.3 million in Q2 2026; TTM through Jun 2026 was $420.3 million, a 15.9% increase from a year earlier, with the FY2025 full-year figure at $393.5 million, up 16.67% from the prior year.
• Common Equity was $420.3 million for Q2 2026 at Lemaitre Vascular, up from $406.6 million in the prior quarter.
• Over five years, Common Equity peaked at $420.3 million in Q2 2026 and troughed at $257.8 million in Q1 2022.
• A 5-year average of $322.0 million and a median of $314.0 million in 2024 frame the typical range for Common Equity.
• The widest YoY moves for Common Equity: up 45.21% in 2022, down 4.9% in 2022.
• Over 5 years, Common Equity stood at $268.2 million in 2022, then advanced by 11.07% to $297.9 million in 2023, then advanced by 13.22% to $337.3 million in 2024, then advanced by 16.67% to $393.5 million in 2025, then climbed by 6.82% to $420.3 million in 2026.
• The last three Common Equity figures came in at $420.3 million (Q2 2026), $406.6 million (Q1 2026), and $393.5 million (Q4 2025), per Business Quant data.